Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

WRONG! HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS

HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.

Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)

https://regenbiopharmainc.com/product-pipeline/

Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
1 IND cleared and 2 INDs submitted with the FDA.
Diverse pre-clinical pipeline including platform technologies .
Strong intellectual property protected by multiple patents